Involved in the biosynthesis of the trisaccharide moiety characteristic of the antitumor drug aclacinomycins. In the first reaction, AknK catalyzes the transfer of 2-deoxy-beta-L-fucose from the activated donor dTDP-2-deoxy-beta-L-fucose to the mono-glycosylated aclacinomycin T (rhodosaminyl aklavinone), forming the di-glycosylated aclacinomycin S (L-2-deoxyfucosyl-L-rhodosaminyl aklavinone). It can also catalyze the addition of an alternate dTDP-L-sugar, dTDP-L-daunosamine, to aclacinomycin T and the addition of 2-deoxy-beta-L-fucose to the mono-glycosylated aglycones (monoglycosylated anthracyclines) such as daunomycin (daunorubicin), adriamycin (doxorubicin) and idarubicin. In vitro, AknK also catalyzes the addition of a second L-2-deoxyfucosyl moiety from dTDP-2-deoxy-beta-L-fucose, albeit with reduced activity, to the natural disaccharide chain of aclacinomycin S to produce L-deoxyfucosyl-L-deoxyfucosyl-L-rhodosaminyl aklavinone (2-deoxy-alpha-D-fucosyl-aclacinomycin S), a variant of the natural aclacinomycin A.

Belongs to the glycosyltransferase 28 family.

440 amino acids

MKVLFTTFAAKSHMHAQVPLAWALQTAGHEVRIASQPDLAEDITRTGLTAVCVGEPLLLEEQMQRVNEGLGDDAEIMESQAEAGMDMTETRPEMLTWDHVLGVFTSMTAMAFQNSCPERMIDDVVAFAREWQPDLIVWDTLSFAGPVAAQVTGAAHARLLFGLDLLGRMRETFLDLQEERLPEQRDDPLREWLTWTLGRYGAEFEEEVAVGQWTVDPVPPSMRFPVKQPFVPLRYIPYNGQAVIPDWLHEPPKKRRVCLTLGVAHREVLDGDRASIGELVEALAELDVEVVATLNEKQLAGMELPDNVRAVDFVPLNALLPTCSAVIHHGGSGTFQTALAHGVPQLIVPDMVWDTIHKAKQLERFGAGLYLHDVDNYTAQDLRDHLLRLLEEPSFAENCARIRREMVGTPSPNDIVPLLEKLTAEHRRDRGARGTVRGEQ

49.2 kDa

(Note: Representative image - actual molecular weight may vary depending on tag type and expression method)

Upon ordering, we will perform rigorous biosecurity and export control screening to ensure that order fulfillment is consistent with all legal and regulatory guidance.

Make aknK using our protein expression services starting at $99 + $.30/amino acid in as fast as two weeks (includes the cost of DNA synthesis)

Order Here